Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT02351115Phase 2Completed

Staccato Alprazolam and Photoparoxysmal Response

Role: collaborator

NCT06525649Phase 1Completed

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042

Role: collaborator

NCT05678881Phase 1Terminated

Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy

Role: collaborator

NCT03531008Completed

Human Epilepsy Project 2: Resistant Focal Seizures Study

Role: collaborator

NCT02126774Completed

The Human Epilepsy Project

Role: collaborator

NCT00616148Phase 2Completed

Efficacy of YKP3089 in Patients With Photosensitive Epilepsy

Role: collaborator

NCT01085461Completed

Assessment of Suicidality in Epilepsy - Rating Tools

Role: lead

NCT00894010Phase 2Completed

Photosensitivity Proof of Concept Trial

Role: lead

All 8 trials loaded